Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Cryoablation of cardiophrenic angle lymph node metastases: a case report

  • Xiaomei Luo1,
  • Weibing He2,
  • Xinan Long2,
  • Gang Fang3,
  • Zhonghai Li4,
  • Rongrong Li5,
  • Kecheng Xu2 and
  • Lizhi Niu3, 6Email author
Journal of Medical Case Reports201711:223

https://doi.org/10.1186/s13256-017-1313-4

Received: 10 August 2016

Accepted: 6 May 2017

Published: 14 August 2017

Abstract

Background

Cardiophrenic angle lymph node metastases are relatively rare. Surgical resection is the main treatment for cardiophrenic angle lymph node metastasis, but it is not always possible.

Case presentation

Here, we report our initial experience with cryoablation of a cardiophrenic angle lymph node metastasis from liver cancer. As the cardiophrenic angle lymph node metastasis was located close to the heart, about 200 mL of 0.9% saline was injected into the pericardium to separate the heart from the target area. The cardiophrenic angle lymph node metastasis was successfully ablated, without any complications.

Conclusions

Cryoablation may be a suitable alternative treatment for cardiophrenic angle lymph node metastasis.

Keywords

Cryoablation Lymphatic metastasis Cardiophrenic angle lymph node

Background

Cardiophrenic angle lymph nodes (CPLN), which are located behind the xiphoid process in the gap between the diaphragm and the heart, are an unusual site for metastases [1]. Although cryoablation has been explored as an option for treating metastatic lesions in patients who cannot undergo surgery or chemotherapy [2], there are no reports of cryoablation techniques applied to CPLN metastasis. Here, we describe a patient with CPLN metastasis from a liver cancer who was successfully treated with cryoablation. The Institutional Review Board of our hospital approved this report.

Case presentation

The patient, a 57-year-old Asian man, was referred to our hospital in February 2016 for treatment of CPLN metastases from liver cancer. In July 2011 he had undergone liver transplantation at a local hospital and had been on antirejection drugs since then. In 2013, at a follow-up review, his serum alpha fetoprotein (AFP) level was seen to be persistently elevated, and the patient was treated with oral sorafenib targeted therapy for 1 year. However, the response was poor, and multiple targeted drugs had been administered since then. In February 2016, a follow-up magnetic resonance imaging (MRI) scan showed an enlarged right cardiophrenic lymph node. A positron emission tomography/computed tomography (PET/CT) examination showed an active nodule between the heart and the diaphragm suggestive of lymph node metastases, involving the parietal pericardium (Fig. 1a). The patient was then referred to our hospital for further treatment.
Fig. 1

Preoperative images. a Follow-up positron emission tomography/computed tomography image at the local hospital; the arrow indicate the cardiophrenic angle lymph node metastasis. b Computed tomography image at our hospital; the size of the node is about 2.3 × 1.7 × 1.8 cm (arrow)

A CT examination at our hospital revealed an enlarged, 2.3 × 1.7 × 1.8 cm, right CPLN, consistent with local metastasis (Fig. 1b). A CT-guided percutaneous lymph node biopsy was performed, and histologic examination confirmed metastasis. Our patient was unwilling to undergo surgery and requested minimally invasive treatment. We explained the options, and our patient chose to undergo cryoablation.

Our patient was fasted for 6 hours before the procedure. The procedure was carried out under CT guidance (SOMATOM Definition 64 AS; Siemens Medical Solutions, Forchheim, Germany), using an argon and helium gas-based system (Endocare, Irvine, CA, USA), two 1.47-mm cryoprobes (Endocare), and a thermal sensor. With our patient supine, the right side of his chest wall was selected as the puncture site and the right cardiophrenic angle as the target tumor area. The skin at the puncture site was anesthetized with 2% lidocaine 5 mL plus 0.75% bupivacaine 5 mL. An 18-gauge needle was inserted into the pericardial cavity under CT guidance. Subsequently, 10 mL of 0.9% saline solution was injected to identify if the tip of needle had entered into the pericardium. Once this was established, about 200 mL of 0.9% saline was injected so that the tumor was well revealed and a safe puncture path was available (Fig. 2b). Next, with CT guidance and continuous close monitoring of vital signs, two 1.47-mm cryoprobes were carefully inserted into the target node in the right cardiophrenic angle (Fig. 2c). Ablation was performed with two 7-minute freezing cycles, with freezing temperature of −130 °C to −150 °C, followed by 3 minutes of thawing. CT was used to visualize the size of the ice ball during the procedure (Fig. 2d) and to confirm that the ice ball had reached sufficient size (3.5 × 3 × 2.8 cm), with a margin of 5 mm beyond the CPLN metastases. The cryoprobes were removed after rewarming. The saline injected into the pericardial cavity was aspirated, the needle withdrawn, and the puncture point was bandaged. His vital signs remained stable throughout the procedure. The total intraoperative blood loss was 2 mL.
Fig. 2

Intraoperative images of the patient. a Computed tomography image before cryoablation; the arrow indicates the tumor. b An 18G needle (arrow) was inserted into the pericardium and 200 mL of 0.9% saline solution was injected. c The thick arrow indicates the cryoprobes and the thin arrow indicates the 18G needle. d Computed tomography image of the ice ball (pink arrow) taken during the procedure to confirm that the ice ball had reached a sufficient size (3.5 × 3 × 2.8 cm3). The pink arrow indicates the cryoprobe

No minor or major complications were noted during or after the procedure. A follow-up CT scan performed 3 days after cryoablation (Fig. 3) showed a 3.5-cm-diameter ablated zone in the right cardiophrenic angle.
Fig. 3

Computed tomography scan images obtained 3 day after cryoablation. The arrow indicate the ablated zone

A follow-up CT scan 1 month later showed a 3.5 × 1.8 × 1.7 cm ablated zone, with no evidence of recurrence (Fig. 4a). Six months later, a follow-up PET/CT examination showed no evidence of recurrence (Fig. 4b).
Fig. 4

Follow-up imaging examination after cryoablation. a Follow-up computed tomography scan 1 month later showed a 3.5 × 1.8 × 1.7 cm ablated zone, with no evidence of recurrence. b Follow-up positron emission tomography–computed tomography examination six month later showed no evidence of recurrence. The arrows indicate the ablated zone

Discussion

The presence of lymph node metastases will upstage a tumor, adversely affect prognosis, and influence treatment choice [1]. Isolated CPLN metastases are relatively rare [3]. While CPLN may be seen in normal subjects, they are usually less than two in number and measure less than 5 mm in diameter [1]. The afferent lymphatics to the CPLN arise from the pericardium, anterior thoracoabdominal body wall, pleura, and parts of the diaphragm, which itself drains lymph from the peritoneum [4]. Tumor lymph drainage is usually along well-recognized lymphatic pathways, but unusual lymph node sites can be involved and may sometimes be the only site of disease, particularly in patients with recurrence.

Cryosurgery is a novel therapeutic approach in benign and malignant tumors, and is especially useful in unresectable tumors [5]. Encouraging results have been reported in lung [6], liver [7], prostate [8], renal [9], and breast cancer [10]. Cryoablation is an attractive option for treating unresectable CPLN metastases.

Cryoablation induces tissue damage mainly through two separate freezing-related events: a direct toxic effect on the cells and an indirect effect via actions on the tumor vasculature, with the end result being a coagulative necrosis [11]. The direct effect involves intra- and extracellular ice formation at temperatures below 0 °C and enzymatic and cell membrane dysfunction, resulting in osmosis of water out of the cells and cellular dehydration. During the thawing cycle, water returns to the intracellular space and causes cellular lysis. The indirect effect is the result of occlusion of small blood vessels because of ice formation [11]. The temperature at the margin of the ice ball is 0 °C, a temperature at which tumor cells can survive; however, 5 mm inside the edge of the ice ball, the temperature is approximately −20 °C to −50 °C, at which temperatures tumor cells are killed. Therefore, in order to achieve complete ablation of tumor tissue, the edge of the ice ball must extend 5 mm beyond that of the tumor [12]. Therefore, in our patient, a margin of at least 5 mm of normal tissue was frozen circumferentially around the tumor.

A major limitation of cryoablation is incomplete destruction of cells at the border of the treated regions where the tissue temperature is greater than −20 °C. The irregular shape of the CPLN and infiltration of surrounding organs also give rise to complications during cryotherapy. For these reasons, adjunctive approaches are required and cryotherapy is usually combined with other treatments. Several authors have reported the use of 5% dextrose in water as the artificial fluid [13, 14]. Because friction between ions is responsible for the heating in radiofrequency ablation (RFA), 5% dextrose in water—which is isotonic and nonionic—could be the ideal buffer solution during RFA. Oura et al., in their study on RFA of breast tumors, reported few skin burns with the use of 5% dextrose in water as the buffer fluid. The fluid protected against skin burns by increasing the distance between the tumor and the skin and by interrupting the radiofrequency waves [15]. Since the heating during microwave ablation is the result of vibration of dipolar molecules rather than the friction of ions, Zhang et al. chose 0.9% saline to create an artificial pleural effusion during microwave ablation of liver tumor and achieved good results, with no complications [16]. In our patient, the CPLN metastasis was located close to the heart, and we chose 0.9% saline solution to create an artificial pericardial effusion to separate the tumor from the heart during cryoablation. This seems to be a feasible approach as our patient tolerated the procedure without any complications.

Conclusions

In conclusion, our results show the potential of cryoablation as a new treatment method for CPLN, particularly in patients in whom surgery is contraindicated. Cryoablation may be a suitable adjunctive therapeutic option for pure CPLN metastasis. However, further prospective investigations with long-term follow-up are needed to confirm our findings.

Abbreviations

AFP: 

Alpha fetoprotein

CPLN: 

Cardiophrenic angle lymph nodes

PET/CT: 

Positron emission tomography/computed tomography

RFA: 

Radiofrequency ablation

Declarations

Acknowledgements

Not applicable.

Funding

Not applicable.

Availability of data and materials

All data and materials are available.

Authors’ contributions

LN is the corresponding author, wrote the script and made substantial contributions to study conception and design. He also was involved in revising it critically for important intellectual content. The patient described in this case report was under LN’s care. XL was involved in drafting the manuscript. WH, XL, GF, ZL, RL, and KX gave final approval of the version to be published and agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. All authors read and approved the final manuscript.

Competing interests

We certify that regarding this manuscript, no actual or potential conflict of interests exist; the work is original, has not been accepted for publication nor is concurrently under consideration elsewhere, and will not be published elsewhere without the permission of the editor and that all the authors have contributed directly to the planning, execution or analysis of the work reported or to the writing of the manuscript.

Ethics approval and consent to participate

Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Medical College, Jinan University
(2)
Department of Oncology, Fuda Cancer Hospital, Jinan University School of Medicine (Guangzhou Fuda Cancer Hospital)
(3)
Department of Surgery and Anesthesia, Fuda Cancer Hospital, Jinan University School of Medicine (Guangzhou Fuda Cancer Hospital)
(4)
Department of Radiology, Fuda Cancer Hospital, Jinan University School of Medicine (Guangzhou Fuda Cancer Hospital)
(5)
Department of Ultrasound, Fuda Cancer Hospital, Jinan University School of Medicine (Guangzhou Fuda Cancer Hospital)
(6)
Guangzhou Fuda Cancer Hospital, School of Medicine, Jinan University

References

  1. Moulding FJ, Roach SC, Carrington BM. Unusual sites of lymph node metastases and pitfalls in their detection. Clin Radiol. 2004;59(7):558–72.View ArticlePubMedGoogle Scholar
  2. Bang HJ, Littrup PJ, Currier BP, Goodrich DJ, Aoun HD, Klein LC, Kuo JC, Heilbrun LK, Gadgeel S, Goodman AC. Percutaneous cryoablation of metastatic lesions from non-small-cell lung carcinoma: initial survival, local control, and cost observations. J Vasc Interv Radiol. 2012;23(6):761–9.View ArticlePubMedPubMed CentralGoogle Scholar
  3. Eguchi T, Takasuna K, Nakayama A, Ueda N, Yoshida K, Fujiwara M. Cardiophrenic angle lymph node metastasis from a fallopian primary tumor. Asian Cardiovasc Thorac Ann. 2012;20(1):74–6.View ArticlePubMedGoogle Scholar
  4. Holloway BJ, Gore ME, A’Hern RP, Parsons C. The significance of paracardiac lymph node enlargement in ovarian cancer. Clin Radiol. 1997;52(9):692–7.View ArticlePubMedGoogle Scholar
  5. Gage AA, Baust JG. Cryosurgery - a review of recent advances and current issues. Cryo Letters. 2002;23(2):69–78.PubMedGoogle Scholar
  6. Inoue M, Nakatsuka S, Yashiro H, Ito N, Izumi Y, Yamauchi Y, Hashimoto K, Asakura K, Tsukada N, Kawamura M, Nomori H, Kuribayashi S. Percutaneous cryoablation of lung tumors: feasibility and safety. J Vasc Interv Radiol. 2012;23(3):295–302.View ArticlePubMedGoogle Scholar
  7. Sheen AJ, Poston GJ, Sherlock DJ. Cryotherapeutic ablation of liver tumours. Br J Surg. 2002;89(11):1396–401.View ArticlePubMedGoogle Scholar
  8. Mouraviev V, Polascik TJ. Update on cryotherapy for prostate cancer in 2006. Curr Opin Urol. 2006;16(3):152–6.View ArticlePubMedGoogle Scholar
  9. Littrup PJ, Ahmed A, Aoun HD, Noujaim DL, Harb T, Nakat S, Abdallah K, Adam BA, Venkatramanamoorthy R, Sakr W, Pontes JE, Heilbrun LK. CT-guided percutaneous cryotherapy of renal masses. J Vasc Interv Radiol. 2007;18(3):383–92.View ArticlePubMedGoogle Scholar
  10. Littrup PJ, Freeman-Gibb L, Andea A, White M, Amerikia KC, Bouwman D, Harb T, Sakr W. Cryotherapy for breast fibroadenomas. Radiology. 2005;234(1):63–72.View ArticlePubMedGoogle Scholar
  11. Sharma A, Moore WH, Lanuti M, Shepard JAO. How I do it: radiofrequency ablation and cryoablation of lung tumors. J Thorac Imaging. 2011;26(2):162–74.View ArticlePubMedGoogle Scholar
  12. Hinshaw JL, Lee Jr FT. Cryoablation for liver cancer. Tech Vasc Interv Radiol. 2007;10(1):47–57.View ArticlePubMedGoogle Scholar
  13. Hinshaw JL, Laeseke PF, Winter 3rd TC, Kliewer MA, Fine JP, Lee Jr FT. Radiofrequency ablation of peripheral liver tumors: intraperitoneal 5% dextrose in water decreases postprocedural pain. AJR Am J Roentgenol. 2006;186(5 Suppl):S306–10.View ArticlePubMedGoogle Scholar
  14. Laeseke PF, Sampson LA, Brace CL, Winter 3rd TC, Fine JP, Lee Jr FT. Unintended thermal injuries from radiofrequency ablation: protection with 5% dextrose in water. AJR Am J Roentgenol. 2006;186(5 Suppl):S249–54.View ArticlePubMedGoogle Scholar
  15. Oura S, Tamaki T, Hirai I, Yoshimasu T, Ohta F, Nakamura R, Okamura Y. Radiofrequency ablation therapy in patients with breast cancers two centimeters or less in size. Breast Cancer. 2007;14(1):48–54.View ArticlePubMedGoogle Scholar
  16. Zhang D, Liang P, Yu X, Cheng Z, Han Z, Yu J, Liu F. The value of artificial pleural effusion for percutaneous microwave ablation of liver tumour in the hepatic dome: a retrospective case-control study. Int J Hyperthermia. 2013;29(7):663–70.View ArticlePubMedGoogle Scholar

Copyright

© The Author(s). 2017

Advertisement